129 related articles for article (PubMed ID: 18855753)
1. Determination of binding potency of peptidic inhibitors of Grb2-SH2 by using the protein-captured biosensor method.
Lung FD; Li WC; Chang YH; Chen HM
Protein Pept Lett; 2008; 15(8):808-10. PubMed ID: 18855753
[TBL] [Abstract][Full Text] [Related]
2. Effects of peptidic antagonists of Grb2-SH2 on human breast cancer cells.
Chen CH; Chen MK; Jeng KC; Lung FD
Protein Pept Lett; 2010 Jan; 17(1):44-53. PubMed ID: 19508206
[TBL] [Abstract][Full Text] [Related]
3. Small nonphosphorylated Grb2-SH2 domain antagonists evaluated by surface plasmon resonance technology.
Lung FD; Chang CW; Chong MC; Liou CC; Li P; Peach ML; Nicklaus MC; Lou BS; Roller PP
Biopolymers; 2005; 80(5):628-35. PubMed ID: 15660381
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives.
Song YL; Peach ML; Roller PP; Qiu S; Wang S; Long YQ
J Med Chem; 2006 Mar; 49(5):1585-96. PubMed ID: 16509576
[TBL] [Abstract][Full Text] [Related]
5. Novel peptide inhibitors for Grb2 SH2 domain and their detection by surface plasmon resonance.
Lung FD; Tsai JY; Wei SY; Cheng JW; Chen C; Li P; Roller PP
J Pept Res; 2002 Sep; 60(3):143-9. PubMed ID: 12213123
[TBL] [Abstract][Full Text] [Related]
6. Surface plasmon resonance thermodynamic and kinetic analysis as a strategic tool in drug design. Distinct ways for phosphopeptides to plug into Src- and Grb2 SH2 domains.
de Mol NJ; Dekker FJ; Broutin I; Fischer MJ; Liskamp RM
J Med Chem; 2005 Feb; 48(3):753-63. PubMed ID: 15689159
[TBL] [Abstract][Full Text] [Related]
7. Solution structure of the Grb2 SH2 domain complexed with a high-affinity inhibitor.
Ogura K; Shiga T; Yokochi M; Yuzawa S; Burke TR; Inagaki F
J Biomol NMR; 2008 Nov; 42(3):197-207. PubMed ID: 18830565
[TBL] [Abstract][Full Text] [Related]
8. Grb2 SH2 domain-binding peptide analogs as potential anticancer agents.
Lung FD; Tsai JY
Biopolymers; 2003; 71(2):132-40. PubMed ID: 12767115
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of Grb2 SH2 Domain Proteins for Mirror-Image Screening Systems.
Noguchi T; Ishiba H; Honda K; Kondoh Y; Osada H; Ohno H; Fujii N; Oishi S
Bioconjug Chem; 2017 Feb; 28(2):609-619. PubMed ID: 28032751
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis by surface plasmon resonance of CD28 interaction with cytoplasmic adaptor molecules Grb2, Gads and p85 PI3K.
Higo K; Oda M; Morii H; Takahashi J; Harada Y; Ogawa S; Abe R
Immunol Invest; 2014; 43(3):278-91. PubMed ID: 24475931
[TBL] [Abstract][Full Text] [Related]
11. Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitor.
Nioche P; Liu WQ; Broutin I; Charbonnier F; Latreille MT; Vidal M; Roques B; Garbay C; Ducruix A
J Mol Biol; 2002 Feb; 315(5):1167-77. PubMed ID: 11827484
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics, free energy, and SPR analyses of the interactions between the SH2 domain of Grb2 and ErbB phosphotyrosyl peptides.
Suenaga A; Hatakeyama M; Ichikawa M; Yu X; Futatsugi N; Narumi T; Fukui K; Terada T; Taiji M; Shirouzu M; Yokoyama S; Konagaya A
Biochemistry; 2003 May; 42(18):5195-200. PubMed ID: 12731860
[TBL] [Abstract][Full Text] [Related]
13. Identification of phosphopeptide ligands for the Src-homology 2 (SH2) domain of Grb2 by phage display.
Gram H; Schmitz R; Zuber JF; Baumann G
Eur J Biochem; 1997 Jun; 246(3):633-7. PubMed ID: 9219519
[TBL] [Abstract][Full Text] [Related]
14. Interaction of the non-phosphorylated peptide G7-18NATE with Grb7-SH2 domain requires phosphate for enhanced affinity and specificity.
Gunzburg MJ; Ambaye ND; Del Borgo MP; Pero SC; Krag DN; Wilce MC; Wilce JA
J Mol Recognit; 2012 Jan; 25(1):57-67. PubMed ID: 22213451
[TBL] [Abstract][Full Text] [Related]
15. Structural and biophysical investigation of the interaction of a mutant Grb2 SH2 domain (W121G) with its cognate phosphopeptide.
Papaioannou D; Geibel S; Kunze MB; Kay CW; Waksman G
Protein Sci; 2016 Mar; 25(3):627-37. PubMed ID: 26645482
[TBL] [Abstract][Full Text] [Related]
16. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands.
Yao ZJ; King CR; Cao T; Kelley J; Milne GW; Voigt JH; Burke TR
J Med Chem; 1999 Jan; 42(1):25-35. PubMed ID: 9888830
[TBL] [Abstract][Full Text] [Related]
17. The Role of Grb2 in Cancer and Peptides as Grb2 Antagonists.
Ijaz M; Wang F; Shahbaz M; Jiang W; Fathy AH; Nesa EU
Protein Pept Lett; 2018 Feb; 24(12):1084-1095. PubMed ID: 29173143
[TBL] [Abstract][Full Text] [Related]
18. NHD2-15, a novel antagonist of Growth Factor Receptor-Bound Protein-2 (GRB2), inhibits leukemic proliferation.
Lewis TR; Smith J; Griffin K; Aguiar S; Rueb KF; Holmberg-Douglas N; Sampson EM; Tomasetti S; Rodriguez S; Stachura DL; Arpin CC
PLoS One; 2020; 15(8):e0236839. PubMed ID: 32780746
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics.
Jiang S; Li P; Peach ML; Bindu L; Worthy KW; Fisher RJ; Burke TR; Nicklaus M; Roller PP
Biochem Biophys Res Commun; 2006 Oct; 349(2):497-503. PubMed ID: 16945340
[TBL] [Abstract][Full Text] [Related]
20. N-terminal carboxyl and tetrazole-containing amides as adjuvants to Grb2 SH2 domain ligand binding.
Burke TR; Yao ZJ; Gao Y; Wu JX; Zhu X; Luo JH; Guo R; Yang D
Bioorg Med Chem; 2001 Jun; 9(6):1439-45. PubMed ID: 11408162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
